A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

20260 citationsJournal Articlehybrid Open Access

Authors

Yousef Zakharia · University of Iowa

Yejin Kim · University of Iowa Health Care

Michele Freesmeier · University of Iowa

Melanie Frees · University of Iowa

Sarah Mott · University of Iowa

Varun Monga · University of California, San Francisco

Douglas Laux ·

Abstract

Cabozantinib and pembrolizumab combination was explored in treatment-naive aCM. Toxicity was consistent with known profiles, but discontinuation rates were notable.

Topics & Keywords

Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers

Publication Details

Published in: Cancer

Volume 132, Issue 4, pp. e70326-e70326

DOI: 10.1002/cncr.70326

Field-Weighted Citation Impact: 0.00

Command Palette

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

Authors

Abstract

Topics & Keywords

Publication Details